Precision Medicine in Oncology®

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.

Serving as gatekeepers at the entry to the cell cycle, CDK4 and CDK6 make ideal therapeutic targets to block the unchecked proliferation that is a hallmark of cancer cells.

A Working Group of the European Society for Medical Oncology has determined that a decision tree on the sequential use of different tests in immunotherapy decision-making cannot be a general one for all cancers but should be designed on the basis of the specific tumor type.

Lynette M. Sholl, MD, discusses the evolving use of liquid and tissue biopsies for next-generation sequencing in the treatment paradigm for patients with lung cancer.

Nathan Pennell, MD, PhD, offers strategies regarding molecular testing in patients with lung cancer and how to address treatment if patients are symptomatic and molecular testing results are unavailable.

Jonathan W. Goldman, MD, health sciences clinical instructor, Department of Medicine, and Hematology/Oncology member, Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics Program, UCLA, discusses the use of immunotherapy in patients with oncogene-driven non–small cell lung cancer (NSCLC).

Hatim Husain, MD, medical oncologist and associate professor of medicine, Moores Cancer Center, University of California, San Diego (UCSD), discusses ongoing research efforts evaluating plasma-based testing in lung cancer.

Gopa Iyer, MD, discusses investigational FGFR inhibitors in metastatic urothelial carcinoma.

Gregory A. Otterson, MD, discusses targetable biomarkers in non–small cell lung cancer.

Lynette M. Sholl, MD, discusses the challenges faced with the use of tissue biopsy to test for biomarkers in lung cancer.

Driven by advances in genetic testing methods and the discovery of actionable mutations beyond BRCA, an update to the National Comprehensive Cancer Network’s Guidelines for genetic testing in breast, ovarian, and pancreatic cancers encompasses a much broader range of genes that predict risk for disease occurrence.

Richard S. Finn, MD, discusses biomarkers of response to immunotherapy in hepatocellular carcinoma.

Gopa Iyer, MD, discusses treatment-emergent hyperphosphatemia with erdafitinib in patients with metastatic urothelial cancer.

Anastasios (Tassos) Dimou, MD, discusses the limitations of tumor mutational burden as a biomarker in lung cancer.

David Polsky, MD, PhD, discusses the unmet need of clinical utility in liquid biopsy.

Single-agent cisplatin did not lead to significantly higher pathologic complete response rates or improved residual cancer burden scores compared with doxorubicin plus cyclophosphamide in the neoadjuvant setting for patients with stage I to III HER2-negative breast cancer who harbor BRCA mutations.